Parkinson's Disease

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 adrenergic agonists might be able to fight Parkinson's disease.

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

By

Patients with postural instability and gait disturbances had worse sleep scores than those with tremor-dominant Parkinson's.

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

By

Enrollment of patients with only early Parkinson's disease in this trial prevents generalization of the study's findings across the entire Parkinson's population.

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

By

Patients with both Parkinson's and rapid eye movement sleep behavior disorder were much more likely to experience mild cognitive impairment.

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

By

Patients taking levodopa therapy may experience neuropsychiatric fluctuations characterized by changes in mood, motivation, and anxiety while in ON and OFF states of drug therapy.

Remote Neurological Care a Feasible Option for Parkinson's Disease

Remote Neurological Care a Feasible Option for Parkinson's Disease

For patient's with Parkinson's disease, virtual house calls from neurologists may be of interest.

Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease

Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease

By

In a disease where there have been few therapeutic developments since dopamine, exenatide offers a promising new channel of exploration.

FDA Approves Parkinson's Dyskinesia Treatment

FDA Approves Parkinson's Dyskinesia Treatment

By

Gocovri is the first treatment for dyskinesia approved for patients with Parkinson's disease who are receiving levodopa therapy.

Algorithm Accurately Predicts Cognitive Decline in Parkinson's Disease

Algorithm Accurately Predicts Cognitive Decline in Parkinson's Disease

By

Patients with the highest predictive scores faced a greater risk of developing cognitive impairment and dementia in the first 10 years after disease onset.

Mislabeled Parkinson's Drug Recalled

Mislabeled Parkinson's Drug Recalled

By

Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

By

Debate continues as to whether ocular tremor represents a clinical marker of Parkinson's disease or a compensatory movement related to other bodily tremors.

Vision Changes May Precede Parkinson's Disease

Vision Changes May Precede Parkinson's Disease

People who experience changes in vision may be at risk for Parkinson's disease.

Parkinson's Patients May Face Greater Risk of Melanoma

Parkinson's Patients May Face Greater Risk of Melanoma

There is a 4 times greater risk of developing melanoma in Parkinson's disease, and vice versa.

Adjunct Therapy for Parkinson's Now Available

Adjunct Therapy for Parkinson's Now Available

By

Xadago tablets have been launched as add-on therapy for Parkinson's disease.

Adjunct Medical Food Holds Benefits for Parkinson's Disease

Adjunct Medical Food Holds Benefits for Parkinson's Disease

By

Previous animal model studies have shown PEA to be beneficial in neuroinflammation and provide neuroprotection.

Dizziness in Parkinson's May Be Caused by Cerebral Hypoperfusion

Dizziness in Parkinson's May Be Caused by Cerebral Hypoperfusion

Transcranial Doppler during head-up tilting may be useful for evaluating dizziness.

Parkinson's Disease Linked to Hepatitis B, C Infection

Parkinson's Disease Linked to Hepatitis B, C Infection

By

People with HBV were 76% more likely and those with HCV were 51% more likely to develop PD than people in the comparison group.

Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease

Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease

By

A significant association was found between the apnea-hypopnea index and Epworth Sleepiness Scale scores.

Novel Assay Identifies Parkinson's Disease Biomarker

Novel Assay Identifies Parkinson's Disease Biomarker

By

Researchers have developed an assay that accurately identifies small quantities of α-synuclein in cerebrospinal fluid.

Regular Exercise Slows Decline Even in Advanced Parkinson's

Regular Exercise Slows Decline Even in Advanced Parkinson's

There were slower declines in health-related quality of life and mobility when exercise was increased by 30 minutes/week.

Safinamide Approved as Adjunctive Therapy for Parkinson's

Safinamide Approved as Adjunctive Therapy for Parkinson's

By

The US FDA has approved safinamide as adjunctive therapy in Parkinson's disease to increase "on" time

Timed Light Therapy May Benefit Sleep in Parkinson's

Timed Light Therapy May Benefit Sleep in Parkinson's

By

Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.

Parkinsonian Disorder Differentiation Using Blood Biomarker

Parkinsonian Disorder Differentiation Using Blood Biomarker

By

Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.

Effect of Depression and Anxiety on Cognition in Parkinson's Disease

Effect of Depression and Anxiety on Cognition in Parkinson's Disease

By

Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.

VIDEO: Dysfunctional Mitochondrial DNA May Play a Role in Parkinson's Disease

VIDEO: Dysfunctional Mitochondrial DNA May Play a Role in Parkinson's Disease

New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.

Cognitive Stress Impacts Levodopa Efficacy in Parkinson's

Cognitive Stress Impacts Levodopa Efficacy in Parkinson's

During cognitive co-activation, the levodopa effect was significantly smaller.

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

By

The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

Developing a Model for Predicting Cognitive Impairment in Parkinson's

Developing a Model for Predicting Cognitive Impairment in Parkinson's

By

A combination of age and clinical scores better predicted cognitive impairment than age alone.

Adjunctive Safinamide Increases On Time in Parkinson's Disease

Adjunctive Safinamide Increases On Time in Parkinson's Disease

By

Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.

Gene Mutation, Age Linked to Early-Onset Parkinson's Disease

Gene Mutation, Age Linked to Early-Onset Parkinson's Disease

Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.

Sign Up for Free e-newsletters